Development of Antimicrobial Peptides as Novel Therapeutics
American Journal of Pharmaceutics · 2020-12-31 · 1 (6) · 1-9
DOI: 10.71465/ajph2092 ↗At a glance
Journal article in American Journal of Pharmaceutics, published online on 2020-12-31. Written by Dr. Adeel Raza. The full text is freely available (open access, CC BY 4.0).
Abstract (original language)
The emergence of multidrug-resistant (MDR) pathogens has escalated the global need for novel antimicrobial strategies. Antimicrobial peptides (AMPs), naturally occurring molecules found in a wide range of organisms, offer a promising alternative to conventional antibiotics. Their unique modes of action, including membrane disruption and immune modulation, make them potent candidates for combating resistant microbes. This article reviews the development of AMPs as therapeutic agents, their mechanisms, challenges in clinical translation, and recent advances in peptide engineering to enhance efficacy and stability. The potential of AMPs to serve as a cornerstone in future antimicrobial therapy is significant, though regulatory and formulation hurdles remain.
Cite
APA
Raza, D. A. (2020). Development of Antimicrobial Peptides as Novel Therapeutics. American Journal of Pharmaceutics, 1(6), 1-9. https://doi.org/10.71465/ajph2092
Vancouver
Raza DA. Development of Antimicrobial Peptides as Novel Therapeutics. American Journal of Pharmaceutics. 2020;1(6):1-9. doi:10.71465/ajph2092
BibTeX
@article{Raza2020,
author = {Raza, Dr. Adeel},
title = {Development of Antimicrobial Peptides as Novel Therapeutics},
journal = {American Journal of Pharmaceutics},
year = {2020},
volume = {1},
number = {6},
pages = {1--9},
doi = {10.71465/ajph2092}
}
EUVIMED